Clinical trial
Study of Talabostat in Advanced Melanoma
NCT00083239 · Point Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00083239 |
|---|---|
| Title | Study of Talabostat in Advanced Melanoma |
| Lead sponsor | Point Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma, Skin Cancer |
| Intervention type | Drug |
| Interventions | talabostat (PT-100) tablets |
| First posted | May 18, 2004 |
| Last update posted | Jun 8, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: